Indian government pushes to expand vaccination of native vaccination for’efficiency controversy’

Indian government pushes to expand vaccination of native vaccination for’efficiency controversy’

by

Sending time2021-01-25 13:39


comment

“Add 7 states to the existing 12 states”… The cumulative number of vaccinations is 1.16 million

Additional vaccine availability reviewed… “Local companies discuss the introduction of Modena vaccine”

Corona 19 vaccine'nose vaccine' made by Indian pharmaceutical company Barat Biotech. [EPA=연합뉴스]

Corona 19 vaccine’nose vaccine’ made by Indian pharmaceutical company Barat Biotech. [EPA=연합뉴스]

(New Delhi = Yonhap News) Correspondent Kim Young-hyun = Indian pharmaceutical company Barat Biotech’s own novel coronavirus infection (Corona 19) vaccine (nose vaccine) was engulfed in’efficacy controversy’, and the authorities rather focused on the vaccine-related vaccination area. I decided to expand.

According to local media such as NDTV on the 24th, Deputy Minister of Health and Family Welfare Manohar Agnani said at a briefing the day before, “From the 25th, we have decided to add 7 states to the existing 12 nasal vaccination states.”

Kovaccine was approved for emergency use on the 3rd, along with AstraZeneca-Oxford University vaccine (Coby Shield) made by the local company Serum Institute (SII).

However, it was pointed out that the Kovaccine was undergoing a phase 3 clinical trial and that the authorities had quickly approved it because even the preventive effect was not disclosed.

Accordingly, the Indian government started vaccination from the 16th, but some subjects are avoiding vaccination because of concerns about the side effects of nasal vaccines, local media reported.

In India, first-time candidates cannot choose the COVID-19 vaccine. The Indian government has emphasized that there is no abnormality in the efficacy of the nose vaccine.

According to the Ministry of Health, 1.16 million people have been vaccinated in India so far.

On the 16th, a hygiene worker receiving a nose vaccine for the first time at AIIMS in New Delhi, India. [로이터=연합뉴스]

On the 16th, a hygiene worker receiving a nose vaccine for the first time at AIIMS in New Delhi, India. [로이터=연합뉴스]

Currently, the authorities are in the process of giving priority vaccinations to 10 million healthcare workers.

Since then, the vaccination will be expanded to 270 million, including 20 million people in the quarantine front, such as police and military personnel, and those in their 50s or older or those under 50 years of age with complications and chronic diseases.

In addition, the Indian authorities are known to be considering supplying three additional vaccines each being developed by local companies, including Sputnik V from Russia, Zydus Kadilla, Biologic E, and Gennova.

“In the coming months, all or some of these four vaccines could be reviewed for emergency use,” said Rajeshi Bushan, vice minister of health.

Separately, the Economic Times reported that the local company’Tata Medical & Diagnosis’ started discussing the introduction of the vaccine with the US pharmaceutical company Modena.

However, unlike AstraZeneca vaccine, which can be stored refrigerated (2-8℃), modena vaccines must be distributed at cryogenic temperatures below -20℃, so it will be difficult to introduce them to India, where medical infrastructure is poor.

Meanwhile, the cumulative number of corona19 confirmed cases in India on that day (based on the Ministry of Health) was 1,667,736, an increase of 13,203 from the previous day.

The cumulative number of deaths and the number of new deaths were 153,470 and 131, respectively.

India's daily number of new cases of Corona 19. [월드오미터 홈페이지 캡처]

India’s daily number of new cases of Corona 19. [월드오미터 홈페이지 캡처]

[email protected]


Unauthorized reproduction-redistribution prohibited>
2021/01/25 13:39 sent

Source